Page 198 - 15Diarrhoeaandvomiting
P. 198
Index
research recommendations selection criteria, xx
antidiarrhoeal agents, 117 semi-structured interview, xx
anti-emetic agents, 18, 109 sensitivity, xx
fluid management, 17, 66 sensitivity analysis, ondansetron health economics, 154
key priorities, 17 septicaemia, indications for investigations, 34
probiotics, 18, 133 serum creatinine, accuracy of dehydration diagnosis, 50
severity of dehydration, 17, 46 Shigella infections
summary, 19 antibiotic therapy, 94, 102
respiratory pattern, abnormal, dehydration detection, 42, 44 community and GP practice incidence, 30
retrospective study, xx duration of diarrhoea, 25
Ringer’s lactate, 58, 68 frequency as cause of traveller’s diarrhoea, 33
WHO recommendation, 71 vitamin A therapy vs placebo, 122
risk, ix shock, xx
risk difference (RD), xx assessment, 38
risk ratio (RR), xix see also hypovolaemic shock
rotavirus infection single-blind study, xx
bismuth subsalicylate trial, 113 skin turgor, xx
clinical features, 24 abnormal, in dehydration, 41, 42, 44
community and GP practice incidence, 30 reduced, hypernatraemic dehydration, 48
costs and burden associated, 2 small round structured viruses, community and GP
duration of diarrhoea, 24, 25 practice incidence, 30
probiotics effect, 129 smectite, 110
frequency, 32 evidence overview, 110
healthcare-associated infections, 29 evidence summary, 111
stool examination, 28, 29 socio-demographic factors, dehydration risk, 39
incidence, 2 sodium
Europe, 29 in oral rehydration fluids, 60, 64
racecadotril vs placebo, 112 serum levels in hypernatraemic dehydration, 47
sequelae after, 24 sodium chloride solution, NPSA recommendation, 71
Royal Colleges, xx solid feeding. see feeding after rehydration
soups, 60
Saccharomyces boulardii, 131 soy formula
Saccharomyces probiotics early vs late refeeding after rehydration, 87
evidence overview, 127 lactose-containing formula vs, after rehydration, 86
see also probiotics solid foods vs, feeding after rehydration, 84
safety netting, xx, 135 with fibre vs without fibre, 124
recommendations, 15, 136 soy polysaccharide (fibre), 117
Salmonella gastroenteritis specificity, xxi
antibiotic therapy, 36, 90 staff costs, 143
ampicillin vs placebo, 91 IVT, 145
ampicillin/amoxicillin vs placebo, 90 ORT, 145
antibiotics vs placebo, 90 stakeholder organisations, vi, 3
azithromycin/cefixime vs placebo, 91 standard deviation (SD), xxi
evidence overview, 90 standardised mean difference (SMD), xxi
evidence summary, 92, 101 Staphylococcus aureus, community and GP practice
GDG interpretation, 101 incidence, 30
indications, 36, 100 statistical power, xxi
intramuscular vs oral, 91 stool microbiological investigation, 27
relapses, 91 enteric pathogen frequency, 27
trimethoprim/sulfamethoxazole vs placebo, 91 children aged under 2 years study, 28
community and GP practice incidence, 30 community studies vs GP, 29, 30
complications, 100 evidence overview, 28
dehydration, 101 evidence summary, 30
duration of diarrhoea, 24, 25 healthcare-associated infections, 28
frequency as cause of traveller’s diarrhoea, 32, 33 population-based study, 29
frequency by year and age, 31 south Wales study, 28
invasive salmonellosis risk factors, 100, 102 specific pathogens by year/age, 31
sequelae after, 24 sub-regional infectious disease hospital study, 28
salmonellosis, invasive, risk factors, 100, 102 surveillance study (1999-2000), 28
sample, xx winter surveillance studies, 29
Scottish Intercollegiate Guidelines Network (SIGN), xx indications for (GDG), 32
secondary care, xx key recommendations, 9
secondary outcome, xx recommendations (indications), 11, 34
selection bias, xx sample collection/transport, 11, 34
173
